Zobrazeno 1 - 10
of 72
pro vyhledávání: '"M. Yu. Frolov"'
Autor:
M. V. Zhuravleva, M. Yu. Frolov, E. A. Luchinin, K. A. Kokushkin, E. D. Laryushkina, T. R. Kameneva, E. V. Kuznetsova
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 2, Pp 42-52 (2023)
Relevance. Cardio-vascular diseases (CVD) are the one of the main reasons of mortality and disability. Hypercholesterinemia is a factor of CVD progression, and thus it should be corrected. Combination of statin + ezetemib is an effective option of a
Externí odkaz:
https://doaj.org/article/c063a5e65d414409b2c30d1d25b16032
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 18, Iss 3, Pp 268-273 (2022)
Aim. To evaluate the impact of a mobile application usage on the self-care skills, quality of life, adherence to treatment, as well as the psychological characteristics of comorbid patients with stable coronary heart disease.Material and methods. The
Externí odkaz:
https://doaj.org/article/ca1b7d6e38b74b899f4ea24565b2bdf3
Publikováno v:
Известия высших учебных заведений: Проблемы энергетики, Vol 23, Iss 6, Pp 16-28 (2022)
THE PURPOSE. The main purpose of the study is to develop the calculation algorithm of energy efficiency indicators. To develop an algorithm, it is necessary to consider the features of the power supply system of the oil and gas production enterprise.
Externí odkaz:
https://doaj.org/article/81375d4148c94df7b877b413c6b8bc54
Publikováno v:
Опухоли женской репродуктивной системы, Vol 17, Iss 3, Pp 97-105 (2021)
Background. According to randomized clinical trial SOLO1 olaparib statistically significantly improves progression-free survival versus placebo as a maintenance monotherapy in patients aged 18 and over with newly diagnosed advanced ovarian cancer wit
Externí odkaz:
https://doaj.org/article/541e4bf2e7d3463b9713e0cb8c3f38ba
Publikováno v:
Современная ревматология, Vol 15, Iss 1, Pp 119-127 (2021)
Objective: to evaluate the economic impact of the use of various biologic disease-modifying antirheumatic drugs (bDMARDs) from the group of inhibitors of interleukins (iIL) 12/23 and iIL17 in adult patients with psoriatic arthritis (PsA) with insuffi
Externí odkaz:
https://doaj.org/article/f0b18f2a639c45d19c33eaa4c1245703
Publikováno v:
Фармакоэкономика, Vol 13, Iss 4, Pp 377-387 (2021)
Aim. The study aimed to assess the economic effect of biological therapy with anti-interleukin (IL)-6 drugs: tocilizumab, olokizumab, and levilimab in patients with severe COVID-19 and cytokine storm.Materials and Methods. An assessment of the econom
Externí odkaz:
https://doaj.org/article/fce342710e504458ad8dc5ce7ffbdd44
Autor:
S. V. Nedogoda, Yu. M. Lopatin, M. V. Arkhipov, A. S. Galyavich, N. A. Koziolova, N. G. Lozhkina, E. V. Reznik, A. S. Salasyuk, M. Yu. Frolov, A. I. Chesnikova, E. V. Chumachek, L. A. Shpagina
Publikováno v:
Российский кардиологический журнал, Vol 27, Iss 2 (2022)
Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.Material and methods. We performed the analysis of outpatient records of 1000 patient
Externí odkaz:
https://doaj.org/article/c457b13f38084408b0d3501b9107c630
Publikováno v:
Фармакоэкономика, Vol 13, Iss 2, Pp 101-111 (2020)
Aim. To assess the economic efficacy of a fixed combination tiotropium bromide+olodaterol (T+O) in comparison with other medications, included in the Vital and Essential Drugs List (VEDL), for the maintenance triple therapy of chronic obstructive pul
Externí odkaz:
https://doaj.org/article/8fb52a2ddbde4e21bc5cee65b83d1275
Publikováno v:
Фармакоэкономика, Vol 12, Iss 4, Pp 279-290 (2020)
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib and abemaciclib are the new treatment options for postmenopausal women with locally advanced or metastatic hormone-receptor (HR) positive human epidermal growth factor recept
Externí odkaz:
https://doaj.org/article/581ce8c0929f46e38f848124732f806e
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 3, Pp 13-22 (2020)
Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2
Externí odkaz:
https://doaj.org/article/553a6426cd0e47598d8fec61af138875